Liposomal codelivery of a synergistic combination of bioactive lipids in the treatment of acute myeloid leukemia

Nanomedicine

Volumn 9, Issue 11, 2014, Pages 1665-1679

  Tan, Kuan Boone ^a   Ling, Leong Uung ^a   Bunte, Ralph M ^b   Chng, Wee Joo ^c,d,e   Chiu, Gigi N C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Singapore Graduate Medical School   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^e Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

acute myeloid leukemia; C2 ceramide; hemolysis; liposome; safingol; sever combined immunodeficiency mouse; sphingolipid; synergistic combination; U937; zeta potential

Indexed keywords

ANTILEUKEMIC AGENT; C2 CERAMIDE; CERAMIDE DERIVATIVE; LIPOSOME; SAFINGOL; UNCLASSIFIED DRUG; 1,2-DISTEAROYLLECITHIN; ANTINEOPLASTIC AGENT; CERAMIDE; CHOLESTEROL; LIPID; N-ACETYLSPHINGOSINE; PHOSPHATIDYLCHOLINE; SPHINGOSINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPARATIVE STUDY; DRUG DOSE REDUCTION; DRUG POTENTIATION; ENCAPSULATION; HUMAN; HUMAN CELL; LIPOSOMAL DELIVERY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; FEMALE; IC50; LEUKEMIA, MYELOID, ACUTE; LIQUID CHROMATOGRAPHY; METABOLISM; SCID MOUSE; TANDEM MASS SPECTROMETRY; U937 CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CERAMIDES; CHOLESTEROL; CHROMATOGRAPHY, LIQUID; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, MYELOID, ACUTE; LIPIDS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, SCID; PHOSPHATIDYLCHOLINES; SPHINGOSINE; TANDEM MASS SPECTROMETRY; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908888112     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.123     Document Type: Article

References (47)

1. Roboz GJ. Novel approaches to the treatment of acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 2011 (1), 43-50 (2011).
2. Bow EJ, Sutherland JA, Kilpatrick MG et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J. Clin. Oncol. 14 (4), 1345-1352 (1996).
3. Milligan DW, Wheatley K, Littlewood T, Craig JIO, Burnett AK; NCRI Haematological Oncology Clinical Studies Group. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 107 (12), 4614-4622 (2006).
4. Virchis A, Koh M, Rankin P et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br. J. Haematol. 124 (1), 26-32 (2004).
5. Feldman EJ, Seiter K, Damon L et al. A randomized trial of high-vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 11 (4), 485-489 (1997).
6. Hasle H, Abrahamsson J, Forestier E et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 120 (5), 978-984 (2012).
7. Fröhling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J. Clin. Oncol. 23 (26), 6285-6295 (2005).
8. Alkan S, Huang Q, Ergin M et al. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am. J. Hematol. 79 (2), 97-106 (2005).
9. Cuvillier O, Levade T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood 98 (9), 2828-2836 (2001).
10. Amin HM, Ergin M, Denning MF, Quevedo ME, Alkan S. Characterization of apoptosis induced by protein kinase C inhibitors and its modulation by the caspase pathway in acute promyelocytic leukaemia. Br. J. Haematol. 110 (3), 552-562 (2000).
11. Dickson MA, Carvajal RD, Merrill AH Jr, Gonen M, Cane LM, Schwartz GK. A Phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin. Cancer Res. 17 (8), 2484-2492 (2011).
12. Jatoi A, Suman VJ, Schaefer P et al. A Phase II study of topical ceramides for cutaneous breast cancer. Breast Cancer Res. Treat. 80 (1), 99-104 (2003).
13. Shabbits JA, Mayer LD. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim. Biophys. Acta 1612 (1), 98-106 (2003).
14. Shikata K, Niiro H, Azuma H, Ogino K, Tachibana T. Apoptotic activities of C2-ceramide and C2-dihydroceramide homologues against HL-60 cells. Bioorg. Med. Chem. 11 (13), 2723-2728 (2003).
15. Demarchi F, Bertoli C, Greer PA, Schneider C. Ceramide triggers an NF-kappa B-dependent survival pathway through calpain. Cell Death Differ. 12 (5), 512-522 (2005).
16. Iwayama H, Ueda N. Role of mitochondrial Bax, caspases, and MAPKs for ceramide-induced apoptosis in renal proximal tubular cells. Mol. Cell. Biochem. 379 (1-2), 37-42 (2013).
17. Taniguchi M, Kitatani K, Kondo T et al. Regulation of autophagy and its associated cell death by "sphingolipid rheostat": reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of rapamycin pathway. J. Biol. Chem. 287 (47), 39898-39910 (2012).
18. Siskind LJ, Colombini M. The lipids C2-and C16-ceramide form large stable channels. Implications for apoptosis. J. Biol. Chem. 275 (49), 38640-38644 (2000).
19. Richter C, Ghafourifar P. Ceramide induces cytochrome c release from isolated mitochondria. Biochem. Soc. Symp. 66, 27-31 (1999).
20. Buehrer BM, Bell RM. Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways. J. Biol. Chem. 267 (5), 3154-3159 (1992).
21. Buehrer BM, Bell RM. Sphingosine kinase: properties and cellular functions. Adv. Lipid Res. 26, 59-67 (1993).
22. Paugh SW, Paugh BS, Rahmani M et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 112 (4), 1382-1391 (2008).
23. Mayer LD, Harasym TO, Tardi PG et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5 (7), 1854-1863 (2006).
24. Feldman EJ, Kolitz JE, Trang JM et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk. Res. 36 (10), 1283-1289 (2012).
25. Perkins WR, Dause RB, Li X et al. Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its hemolytic activity. Biochim. Biophys. Acta 1327 (1), 61-68 (1997).
26. Lee S, Kim J, Shim G et al. Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor. J. Control. Release 164 (2), 213-220 (2012).
27. Zhukova MV, Romanenko OV, Nikolaevich VA, Kisel MA. Hemolytic properties of miltefosine in liposomes of various lipid compositions. Pharm. Chem. J. 44 (9), 507-509 (2010).
28. Tan K-B, Ling L-U, Bunte RM, Chng W-J, Chiu GNC. In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia. J. Control. Release 160 (2), 290-298 (2012).
29. Feldman EJ, Lancet JE, Kolitz JE et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 29 (8), 979-985 (2011).
30. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65 (1), 36-48 (2013).
31. Ling LU, Tan KB, Lin H, Chiu GNC. The role of reactive oxygen species and autophagy in safingol-induced cell death. Cell Death Dis. 2, e129 (2011).
32. Ling LU, Tan KB, Chiu GNC. Role of reactive oxygen species in the synergistic cytotoxicity of safingol-based combination regimens with conventional chemotherapeutics. Oncol. Lett. 2 (5), 905-910 (2011).
33. Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J. Biol. Chem. 66 (2), 375-400 (1925).
34. Kedderis LB, Bozigian HP, Kleeman JM et al. Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam. Appl. Toxicol. 25 (2), 201-217 (1995).
35. Cullis PR, Kruijff BD. Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim. Biophys. Acta 559 (4), 399-420 (1979).
36. Johnsson M, Edwards K. Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids. Biophys. J. 85 (6), 3839-3847 (2003).
37. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Synergism and Antagonism in Chemotherapy. Chou TC, Rideout DC (Eds). Academic Press, CA, USA (1991).
38. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 9 (2), 139-150 (2008).
39. Perkins WR, Dause RB, Li X et al. Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its hemolytic activity. Biochim. Biophys. Acta 1327 (1), 61-68 (1997).
40. Watters RJ, Kester M, Tran MA, Loughran Jr TP, Liu X. Development and use of ceramide nanoliposomes in cancer. In: Methods in Enzymology. Nejat D (Ed.). Academic Press, CA, USA, 89-108 (2012).
41. Appelbaum FR, Rosenblum D, Arceci RJ et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109 (5), 1810-1816 (2007).
42. Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem. Biol. Interact. 184 (1-2), 16-20 (2010).
43. Torrecillas A, Aroca-Aguilar JD, Aranda FJ et al. Effects of the anti-neoplastic agent ET-18-OCH3 and some analogs on the biophysical properties of model membranes. Int. J. Pharm. 318 (1-2), 28-40 (2006).
44. Koshkaryev A, Piroyan A, Torchilin VP. Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer Biol. Ther. 13 (1), 50-60 (2012).
45. Chiu GN, Bally MB, Mayer LD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim. Biophys. Acta 1510 (1-2), 56-69 (2001).
46. Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 70 (2), 440-446 (2010).
47. Chiu GN, Wong MY, Ling LU et al. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities. Curr. Drug Metab. 10 (8), 861-874 (2009).